Literature DB >> 20088628

The impact of depression on workplace functioning and disability costs.

Wayne Katon1.   

Abstract

Until recently, the negative effect that major depressive disorder (MDD) has on interpersonal and workplace functioning had not been widely studied. Traditionally, the goals for treating MDD have also not focused on the commonly associated increases in healthcare utilization for somatic symptoms (ie, headache, abdominal pain) and poorly controlled comorbid medical illnesses, which lead to higher healthcare costs. This article reviews the extensive data collected during the past 10 years that have quantified the impact that MDD has on these outcomes, suggesting that patients with MDD have significant decrements in function, particularly those with comorbid general medical conditions. Also reviewed is the literature presenting evidence from randomized trials of systematic and collaborative treatment efforts that optimize treatment response and, in turn, decrease interpersonal disability, long-term healthcare costs, and the costs associated with lost productivity and absenteeism in the workplace. Such treatment models include algorithmically derived treatment alternatives and collaborative care models, which use a team approach to ensure treatment adherence and to monitor symptom response and side effects. The benefits of using disability assessment measures in conjunction with routine monitoring of depressive symptoms are also discussed.

Entities:  

Mesh:

Year:  2009        PMID: 20088628

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  16 in total

1.  Association between low serum 25-hydroxyvitamin D and depression in a large sample of healthy adults: the Cooper Center longitudinal study.

Authors:  MinhTu T Hoang; Laura F Defina; Benjamin L Willis; David S Leonard; Myron F Weiner; E Sherwood Brown
Journal:  Mayo Clin Proc       Date:  2011-11       Impact factor: 7.616

2.  Improving work outcomes of dysthymia (persistent depressive disorder) in an employed population.

Authors:  David A Adler; Debra Lerner; Zachary L Visco; Annabel Greenhill; Hong Chang; Elina Cymerman; Francisca Azocar; William H Rogers
Journal:  Gen Hosp Psychiatry       Date:  2015-04-08       Impact factor: 3.238

3.  Severity of depression and magnitude of productivity loss.

Authors:  Arne Beck; A Lauren Crain; Leif I Solberg; Jürgen Unützer; Russell E Glasgow; Michael V Maciosek; Robin Whitebird
Journal:  Ann Fam Med       Date:  2011 Jul-Aug       Impact factor: 5.166

4.  The Relation Between Catastrophizing and Occupational Disability in Individuals with Major Depression: Concurrent and Prospective Associations.

Authors:  Heather Adams; Pascal Thibault; Tamra Ellis; Emily Moore; Michael Sullivan
Journal:  J Occup Rehabil       Date:  2017-09

5.  The effect of depression treatment on work productivity.

Authors:  Arne Beck; Lauren A Crain; Leif I Solberg; Jürgen Unützer; Michael V Maciosek; Robin R Whitebird; Rebecca C Rossom
Journal:  Am J Manag Care       Date:  2014-08-01       Impact factor: 2.229

6.  Development of Neuroimaging-Based Biomarkers in Major Depression.

Authors:  Kyu-Man Han; Byung-Joo Ham; Yong-Ku Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Treatment progress indicator: application of a new assessment tool to objectively monitor the therapeutic progress of patients with depression, anxiety, or behavioral health impairment.

Authors:  Phillip Tuso
Journal:  Perm J       Date:  2014-06-09

8.  Unpacking Collaborative Care for Depression: Examining Two Essential Tasks for Implementation.

Authors:  Yuhua Bao; Benjamin G Druss; Hye-Young Jung; Ya-Fen Chan; Jürgen Unützer
Journal:  Psychiatr Serv       Date:  2015-11-16       Impact factor: 3.084

9.  Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors.

Authors:  Mike Briley; Chantal Moret
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

10.  Improvement of the noradrenergic symptom cluster following treatment with milnacipran.

Authors:  Siegfried Kasper; Diana Meshkat; Alexandra Kutzelnigg
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-31       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.